The American Journal of GASTROENTEROLOGY VOLUME 111 | JANUARY 2016 www.amjgastro.com
THE RED SECTION
Celiac disease now aff ects nearly 1% of the population of the United States ( 1 ), and diagnosis rates have continued to increase in recent years ( 2 ) . Th e rise in celiac disease diagnoses does not merely refl ect an increased awareness of this immune-based condition on the part of patients and physicians. Th e seroprevalence of markers for celiac disease among asymptomatic individuals has risen markedly (four-to-fi vefold) in recent decades ( 3 ) . Although the genetic basis of celiac disease has been well established, including a necessary set of human leukocyte antigen (HLA) haplo types and multiple weaker relationships identifi ed by genome-wide association studies, the rapidity of this rise points to the role of the environment in triggering the loss of immune tolerance to gluten.
It has long been thought that it may be possible to reduce the likelihood of celiac disease in children by prolonged breastfeeding and altering the introduction of timing of gluten to the diet of infants at risk of celiac disease. An epidemic of celiac disease among young children in Sweden during the 1980s and 1990s was attributed to a number of feeding practices thought to be conducive to the loss of tolerance to gluten, including a lack of breastfeeding and a high gluten content during its fi rst introduction ( 4 ) . Th e notion of a "window of tolerance" was supported by a prospective cohort study that found that the risk of celiac disease was greater among infants whose fi rst exposure to gluten occurred prior to age 4 months or beyond age 6 months ( 5 ). Th e mechanism for this "window of tolerance" was thought to be related to the relationship between gluten and the gut barrier; introduction prior to maturation of this barrier (prior to 4 months), or a large initial gluten load aft er 6 months, may induce innate immune activation ( 5 ) . However, the fact that these inferences were drawn from observational studies, as well as inconsistent fi ndings regarding the protective eff ect of breastfeeding ( 6 ) , left some uncertainty about the optimal approach to prevent celiac disease.
Two recently published randomized trials of infant feeding practices have now brought the strategy of environmental intervention into sharp relief. Th eir results provide clarity for prospective parents of newborns at risk for celiac disease as well as reassurance for parents who have oft en wondered if whatever feeding practice they took might have contributed to the risk of celiac disease in their children. Th ese studies were large, multicenter, with long-term follow-up, and the results of their interventions were resoundingly negative.
Th e fi rst study, conducted at 20 centers throughout Italy, compared a delayed strategy of introduction of gluten at 12 months 
of age with the standard strategy of 6 months of age ( 7 ) . Th e 553 children in this trial were all at increased risk for developing celiac disease, as they had a compatible HLA haplotype and a fi rst-degree relative with celiac disease. Th e cumulative prevalence of celiac disease at age 10 years was 16.8% (see Table 1 ). Th is intervention study showed that, although the later introduction of gluten delayed the onset of celiac disease in early childhood, there was no diff erence between the two groups by the age of 5 or 10 years, suggesting that age of introduction of gluten had very little impact on the ultimate risk for celiac disease later in childhood. It therefore appears that delaying gluten introduction may delay the onset of celiac disease but does not reduce its incidence.
Th e second study, a double-blind placebo-controlled trial conducted in eight countries, tested the commonly recommended practice of introducing small amounts of gluten at 4 months of age ( 8 ) . Infants ( n= 944) with an at-risk HLA haplotype and a fi rstdegree relative with celiac disease were randomly assigned either 200 mg of vital wheat gluten or placebo at that age, and then dietary gluten was introduced to both groups at age 6 months. It had been thought that this intervention of low-dose gluten exposure at an early age would give the immune system the opportunity to learn to tolerate gluten. At age 5 years, the cumulative prevalence of celiac disease was 12.1%, and there was no signifi cant diff erence in risk of celiac disease when comparing the intervention with the placebo group (hazard ratio, 1.23; 95% confi dence interval, 0.79-1.91).
Moreover, in neither trial was breastfeeding duration found to have any eff ect on the risk of celiac disease. Th is fi nding is in contrast to the protective eff ect of breastfeeding found in a number of autoimmune diseases, including type 1 diabetes ( 9 ), multiple sclerosis ( 10 ), and rheumatoid arthritis ( 11 ) . Th ese protective eff ects have been attributed to the fact that human breast milk contains numerous immunomodulating, as well as antimicrobial molecules. Th ese include immunoglobulins, lactoferrin, alpha-lactalbumin, oligosaccharides and glycoconjugates, lipids, nucleotides, growth factors, and cytokines. Breast milk contains leukocytes that can be taken up by the infant and provides immunological protection and transfer of information ( 12 ) . Breastfeeding also appears to promote a gut microbiome that enhances epithelial barrier ( 13 ) . Despite multiple plausible mechanisms, these trials did not fi nd a protective eff ect of breastfeeding with regard to the risk of celiac disease.
Where to next? We must acknowledge that these null results are unequivocal and disappointing. Th e promise suggested by observational studies, together with our notions regarding how and why celiac disease develops, has met the stark reality of two well-designed trials that both failed to demonstrate a way to reduce the risk of celiac disease. Th ese results indicate that, in this population of children at high risk for celiac disease, the practice of modifying the quantity or delaying the timing of the introduction of gluten to 12 months or introducing gluten between 4 and 6 months likely has little eff ect.
However, disappointment should not lead to nihilism. Rather, this is a "back to the drawing board" moment for the celiac disease community. Th ese results must bring us back to focus on what environmental factors may be operating in these children at risk for celiac disease and how these environmental factors interact with their increased genetic risk to produce celiac disease at such a young age.
It remains indisputable that gluten is the key environmental trigger of celiac disease, and is central to its pathogenesis. However, the rise in celiac disease prevalence in recent decades, in the face of stable genes in this relatively short time span, mandates a hunt for other environmental elements that have tilted increasing numbers toward the loss of gluten tolerance. A recent international observational study of children found that residence in Sweden was associated with a doubling of celiac disease risk compared with that of the United States, independent of sex, family history, or HLA type, pointing to some unknown environmental exposure ( 14 ) . A host of environmental risk factors for celiac disease have been proposed in recent years based on observational studies. Th ese include prenatal exposures, such as maternal iron use during pregnancy ( 15 ) , and infections in children and adults with rotavirus ( 16 ) and Campylobacter jejuni ( 17 ) . Th e increased risk of celiac disease aft er exposure to antibiotics ( 18 ) or to elective caesarian section ( 19 ) points toward the microbiome as having a modulatory eff ect on celiac disease risk. It may be the case that individuals at risk for celiac disease develop it in adulthood when an environmental factor such as an infection, medication, or dietary change destabilizes the microbiome. Pending corroboratory evidence relating any or all of these factors to celiac disease pathogenesis, these proposed risk factors may be promising candidates for exploratory prospective studies ( 20 ) . It should also be noted that the role of epigenetic factors has not been addressed. 
Th ese trials also underscore the importance of HLA haplotype on the risk of developing celiac disease. Indeed, in both studies, the main predictor of celiac disease was the HLA haplotype. In those children with the highest genetic risk type for celiac disease, over one quarter of children developed evidence of celiac disease at an early age (see Table 1 ). Th is has practical implications both for the design of future intervention trials (which could be restricted to the most such high-risk patients and appropriately powered) and for the everyday clinical practice. It may be warranted to undertake genetic testing of children at high risk for celiac disease early in life and then identify those who need vigilance for the onset of celiac disease, warranting a low threshold for repeated serological testing.
Given the heroic eff orts involved in the design and execution of these clinical trials, we should use the collective action of the celiac disease scientifi c community to derive as much knowledge as possible from these studies, so as to generate hypotheses and direction for future investigations. As such, the data from these intervention trials should be made available in de-identifi ed form to interested investigators.
We should also recognize that, although these negative results are frustrating to parents who are looking for ways to reduce the risk of celiac disease in their children, several promising research developments in the treatment of celiac disease have occurred in recent years. Th e mainstay of treatment remains a strict glutenfree diet, but multiple non-dietary therapies are in various phases of testing. Th ese include pretreatment of gluten prior to ingestion, intraluminal digestion of gluten during meals, enhancement of intestinal tight junctions, inhibition of transglutaminase, and other mechanisms ( 21 ) .
Although these studies of high-risk children provide some longawaited answers, they also raise more questions. Do these results apply to the general population of low risk individuals who do not have a family history of celiac disease? Can tolerance to gluten in celiac disease be regained, as has been observed in a proportion of children who develop a transient elevation of transglutaminase antibody levels ( 22 ) ? Could infant feeding practices aff ect the chance of regaining tolerance? Why are we seeing far more celiac disease, despite the fact that wheat consumption has decreased over the past century? Does vital gluten that is added to wheat fl our have a role? How can celiac disease occur at any age, even in people who have been exposed to gluten for many years? Th ese are crucial questions that need to be answered if we are to turn back the rising tide of the celiac disease epidemic.
